On Jan. 19, 2021, Heat Biologics announced it had transferred its gp96-based COVID-19 vaccine cell line (“ZVX-60”) to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which was being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.